French scientists also report that Ligilactobacillus salivarius CNCM I-4866 does not contain the genes for antibiotic resistance and mainly produces L-lactate with very little D-lactate. Animal data indicates that L-lactate may alleviate intestinal inflammation, while accumulation of D-lactate can lead to detrimental effects in people with short bowel syndrome.
“Our study has shown that a new strain, L. salivarius CNCM I-4866, displays strong anti-inflammatory capacities in vitro and in vivo,” scientists from INRAE at the Université Paris-Saclay wrote in the journal Frontiers in Microbiology.
“Even if further research could be useful to better understand the mechanisms involved or to test this strain on moderate inflammation, CNCM I-4866 is confirmed to be a promising probiotic candidate to alleviate inflammation at the preclinical level on a DNBS model, mimicking IBD and, more specifically, Crohn’s disease.”
Study details
Led by Célia Carbonne and Rebeca Martin, the researchers assessed the safety and efficacy of L. salivarius CNCM I-4866, which was as isolated by French company Sorbial. The strain’s potential anti-inflammatory properties were investigated using a mouse model of acute inflammation colitis induced by a chemcical called dinitrobenzene sulfonic acid (DNBS).
Results of the DNMS experiment indicated that the CNCM I-4866 group of mice displayed less intestinal permeability (which is known to increase with inflammation) and to decrease select biomarkers of inflammation.
Additional in vitro experiments supported these initial findings, with data showing promotion of an anti-inflammatory effect by decreasing, for example, the production of IL-8, a pro-inflammatory marker.
Moreover, the strain was found to inhibit several intestinal pathogens, such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and S. enteritidis.
The researchers also investigated the strain’s technical and safety profile, noting that no antibiotic gene resistance was found, and the strain was “highly resistant to 0.3% of bile salts”.
“Taken together, these results indicate that L. salivarius CNCM I-4866 could be a good probiotic candidate for intestinal inflammation, especially with its steady anti-inflammatory profile,” concluded the researchers.
Source: Frontiers in Microbiology
Volume 14 – 2023, doi: 10.3389/fmicb.2023.1270974
“Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo”
Authors: C. Carbonne, et al.
